We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Specifies Bioequivalence Study Designs in Draft Guidance
FDA Specifies Bioequivalence Study Designs in Draft Guidance
Generic drug sponsors should use the highest strength of the drug in their pivotal bioequivalence studies, unless safety considerations forbid that, the FDA recommends in a new guidance.